

ICMJE DISCLOSURE FORM

Date: 29 June 2021

Your Name: Martin J. Edelman

Manuscript Title: Role of induction and adjuvant systemic treatment in mesothelioma

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None	Glaxo Smith Kline (institution)
			Windmil (institution)
			Nektar (institution)
			Revolutions Medicine (institution)
			Adaptimmune (institution)
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input type="checkbox"/> None	Windmil (personal)
			Flame (personal)

			Kanaph (personal)
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None	Sanofi (lecture, paid)
			Sanofi/Genzyme/Regeneron (advisory board, paid)
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input type="checkbox"/> None	Nektar (reimbursement for investigator meeting)
8	Patents planned, issued or pending	<input type="checkbox"/> None	Radiopharmaceutical for the treatment of small cell
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> None	Astra-Zeneca
			Takeda
			Seattle Genetics
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None	Lung Cancer (journal) (paid)
			Lung Cancer Foundation of America (unpaid)
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

Dr. Edelman has reports the following:
 Grants and contracts to his institution for clinical research from GSK, Windmil, Nektar, Revolutions Medicine and Adaptimmune.
 DSMB membership for trials sponsored by Astra Zeneca, Takeda, Seattle Genetics
 Consulting fees from Windmil, Kanph, Sanofi
 Lecture fees from Sanofi
 Reimbursement for travel from Nektar.
 Deputy Editor for "Lung Cancer" and Chair of the Scientific Advisory Board for the Lung Cancer Foundation of America

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.